Evidence map›Paper›PMID 42062270›Full record

ArticleNature communications2026

Alternative enzymatic pathways to penicillin antibiotics.

Puja Saha, Guangcai Xu, Deepanjan Panda, Duncan Smith, Wei Li Thong, Luke Ward, Luis Bering, Sebastian Cuesta-Hoyos, Sarah A Shepherd, Jason Micklefield

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Puja SahaDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK.
Guangcai XuDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK.ORCID http://orcid.org/0000-0003-4074-5165
Deepanjan PandaDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK.
Duncan SmithDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
Wei Li ThongDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
Luke WardDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0009-0009-2391-3295
Luis BeringDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
Sebastian Cuesta-HoyosDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
Sarah A ShepherdDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-7321-1234
Jason MicklefieldDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, London, UK. j.micklefield@imperial.ac.uk.ORCID http://orcid.org/0000-0001-8951-4873

Funding

Innovate UK BB/N023536/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/X002241/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/X008991/1
6 · The paper itself

Abstract

The discovery of penicillin, more than a century ago, has been one of the most significant advances in medicine. Despite the growing threat of antimicrobial resistance, which has rendered many other antibiotics ineffective, penicillin derivatives remain among the most widely prescribed antibiotics. Penicillin is biosynthesised by a large nonribosomal peptide synthetase (NRPS) enzyme, which assembles a tripeptide precursor ACV. This intermediate is subsequently cyclised by isopenicillin N synthase (IPNS) to form penicillin. ACV is similar in structure to glutathione, a ubiquitous, tripeptide antioxidant essential for aerobic life forms. Unlike ACV, glutathione is assembled using simpler ligase enzymes rather than complex NRPS machinery. In this paper, we describe an alternative pathway to penicillins that uses stand-alone ligase and epimerase enzymes to generate peptide precursors, which can be transformed to penicillin derivatives using an engineered IPNS enzyme. Unlike the native NRPS assembly line, the ligase pathway provides direct access to therapeutically relevant penicillin G, penicillin V and ampicillin, which are currently produced by semi-synthesis.

Indexed as

Anti-Bacterial AgentsOxidoreductasesPenicillinsPeptide SynthasesAmpicillinBacterial ProteinsPenicillin GPenicillin VAmpicillinAnti-Bacterial AgentsBacterial Proteinsisopenicillin N synthetaseOxidoreductasesPenicillin GPenicillinsPenicillin VPeptide Synthases

Identifiers

PMID42062270
PMCPMC13338154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.